BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating

Stock News11:08

BOCOM International has released a research report raising its price target for BEONE MEDICINES (06160) from HKD 229.2 to HKD 276, while maintaining a "Buy" rating.

In the second quarter, Zanubutinib from BEONE MEDICINES once again delivered sales results exceeding expectations, driven by factors such as expanded indications, deeper penetration of new patients, enhanced compliance, and improved duration of therapy (DoT). Meanwhile, Tislelizumab is beginning to accelerate its overseas sales volume, and its future combination with HER2 bispecific antibodies will unlock treatment opportunities in first-line HER2+ gastric cancer.

The firm has raised its net profit forecasts for BEONE MEDICINES for the years 2026 through 2028 to USD 1.026 billion, USD 1.5 billion, and USD 2.008 billion, respectively. This revision reflects the company's stronger-than-expected second-quarter performance and the latest guidance provided.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175410099?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175410099","market":"nz","top_or_hot":-1,"title":"BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating","media":"Stock News","content":"<p>BOCOM International has released a research report raising its price target for <b>BEONE MEDICINES (06160)</b> from HKD 229.2 to HKD 276, while maintaining a \"Buy\" rating.<br><br>In the second quarter, Zanubutinib from <b>BEONE MEDICINES</b> once again delivered sales results exceeding expectations, driven by factors such as expanded indications, deeper penetration of new patients, enhanced compliance, and improved duration of therapy (DoT). Meanwhile, Tislelizumab is beginning to accelerate its overseas sales volume, and its future combination with HER2 bispecific antibodies will unlock treatment opportunities in first-line HER2+ gastric cancer.<br><br>The firm has raised its net profit forecasts for <b>BEONE MEDICINES</b> for the years 2026 through 2028 to USD 1.026 billion, USD 1.5 billion, and USD 2.008 billion, respectively. This revision reflects the company's stronger-than-expected second-quarter performance and the latest guidance provided.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-10 11:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BOCOM International has released a research report raising its price target for <b>BEONE MEDICINES (06160)</b> from HKD 229.2 to HKD 276, while maintaining a \"Buy\" rating.<br><br>In the second quarter, Zanubutinib from <b>BEONE MEDICINES</b> once again delivered sales results exceeding expectations, driven by factors such as expanded indications, deeper penetration of new patients, enhanced compliance, and improved duration of therapy (DoT). Meanwhile, Tislelizumab is beginning to accelerate its overseas sales volume, and its future combination with HER2 bispecific antibodies will unlock treatment opportunities in first-line HER2+ gastric cancer.<br><br>The firm has raised its net profit forecasts for <b>BEONE MEDICINES</b> for the years 2026 through 2028 to USD 1.026 billion, USD 1.5 billion, and USD 2.008 billion, respectively. This revision reflects the company's stronger-than-expected second-quarter performance and the latest guidance provided.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1303224171.USD","symbol_name":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1175410099","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175410099","pubTimestamp":1786331293,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BOCOM International has released a research report raising its price target for BEONE MEDICINES (06160) from HKD 229.2 to HKD 276, while maintaining a \"Buy\" rating.In the second quarter, Zanubutinib...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BK4526":"热门中概股","BK4139":"生物科技","BK0239":"医药制造","BK1583":"高瓴概念","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","ONC":"百济神州","EWH":"香港ETF-iShares MSCI","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4588":"碎股","BK1500":"做空集合股","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","06160":"百济神州","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","BK1161":"生物科技","BK1588":"回港中概股","LU0228659784.USD":"施罗德金砖四国基金","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","KURE":"KraneShares MSCI All China Health Care Index ETF"},"translate_title":"交银国际上调BEONE MEDICINES目标价至276港元，维持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"ONC":1,"KURE":1,"06160":1,"EWH":1},"content_text":"BOCOM International has released a research report raising its price target for BEONE MEDICINES (06160) from HKD 229.2 to HKD 276, while maintaining a \"Buy\" rating.In the second quarter, Zanubutinib from BEONE MEDICINES once again delivered sales results exceeding expectations, driven by factors such as expanded indications, deeper penetration of new patients, enhanced compliance, and improved duration of therapy (DoT). Meanwhile, Tislelizumab is beginning to accelerate its overseas sales volume, and its future combination with HER2 bispecific antibodies will unlock treatment opportunities in first-line HER2+ gastric cancer.The firm has raised its net profit forecasts for BEONE MEDICINES for the years 2026 through 2028 to USD 1.026 billion, USD 1.5 billion, and USD 2.008 billion, respectively. This revision reflects the company's stronger-than-expected second-quarter performance and the latest guidance provided.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175410099","isCrawlerRequest":true}